Gout: ACR 2020 Management, Urate-Lowering Therapy, and Flare Control
Executive Summary
Gout is the most common inflammatory arthritis in adults and is curable in the sense that sustained reduction of serum urate below 6 mg/dL dissolves monosodium urate deposits and eliminates flares. The ACR 2020 guideline endorses a disciplined treat-to-target approach: start urate-lowering therapy in any patient with ≥2 flares per year, tophi, radiographic damage, CKD stage ≥3, or urolithiasis; use allopurinol first-line (start 100 mg daily, or 50 mg in CKD; titrate every 2-5 weeks to urate <6); screen HLA-B*5801 in Southeast Asian and Black patients before allopurinol; co-administer anti-inflammatory prophylaxis (low-dose colchicine 0.6 mg daily, low-dose NSAID, or prednisone <10 mg) for at least 3-6 months after target achievement to prevent mobilization flares. Acute flares respond to NSAIDs, colchicine with a pulsed 1.2 mg/0.6 mg regimen, or prednisone 30-40 mg × 5 days; the choice is driven by comorbidities (renal function, GI bleeding risk, heart failure, diabetes). Never stop ULT during a flare.
Contents
- Pathophysiology and Risk Factors
- Hyperuricemia sources
- Drug and dietary triggers
- Diagnosis and Classification
- Crystal identification
- Imaging and ACR/EULAR criteria
- Acute Flare Management
- Urate-Lowering Therapy (ULT)
- Allopurinol titration
- Febuxostat, probenecid, pegloticase
- Comorbidities and Referral
- Practice Insights
- Pearls, Pitfalls, and FAQ
S1. Pathophysiology and Risk Factors
Monosodium urate (MSU) precipitates when serum urate exceeds its solubility limit (6.8 mg/dL at 37°C, lower at joint temperatures of 32-35°C—hence podagra at the cold distal first metatarsophalangeal joint). Crystals deposited in synovium and cartilage activate the NLRP3 inflammasome within resident macrophages, releasing IL-1β and recruiting neutrophils that amplify acute inflammation. Chronic deposits organize into tophi—granulomatous collections of MSU surrounded by chronic inflammatory cells that erode bone and cartilage over years.
Sources of hyperuricemia
The majority of gout patients (about 90 percent) are urate underexcretors rather than overproducers—urinary uric acid excretion is below 600 mg/24h on a normal diet despite elevated serum urate. Underexcretion is driven by CKD, diuretics (thiazides, loop), low-dose aspirin (<2 g/day), cyclosporine, tacrolimus, and pyrazinamide. Overproduction (24h urinary uric acid >800 mg) results from purine-rich dietary excess, fructose intake, lymphoproliferative and myeloproliferative disorders, hemolysis, rhabdomyolysis, tumor lysis syndrome, and rare inherited enzymopathies (HGPRT deficiency, PRPP synthetase overactivity).
Dietary and drug triggers
| Trigger category | Examples | Mechanism |
|---|---|---|
| High-purine food | Organ meats, red meat, sardines, anchovies, shellfish | Purine load → urate production |
| Alcohol | Beer > spirits; wine lowest | Ethanol metabolism → lactate → renal urate retention; beer adds purines (guanosine) |
| Fructose / high-fructose corn syrup | Sweetened beverages, juice | ATP depletion in hepatocytes → urate production |
| Diuretics | Thiazides, loop diuretics | Volume contraction → proximal tubular urate reabsorption |
| Low-dose aspirin | <2 g/day (cardioprotective) | Proximal tubular urate reabsorption; do not discontinue for CV indication |
| Calcineurin inhibitors | Cyclosporine, tacrolimus | Reduced urate clearance; post-transplant gout common |
| Urate-lowering comorbidity drugs | Losartan, fenofibrate, SGLT2 inhibitors | Mildly uricosuric; prefer in hypertensive/dyslipidemic gout patients |
S2. Diagnosis and Classification
Gold standard: synovial fluid crystal analysis
Joint aspiration with polarized light microscopy is definitive. MSU crystals are needle-shaped, 2-20 µm long, strongly negatively birefringent (yellow when parallel to the polarizer axis, blue when perpendicular). Calcium pyrophosphate (CPPD/pseudogout) crystals are rhomboid and weakly positively birefringent. Aspirate tophi, effusions, and even asymptomatic previously affected joints between flares—crystals persist for months and support diagnosis in atypical presentations. Synovial WBC counts in acute gout range from 10,000-100,000/µL with >75 percent neutrophils; Gram stain and culture exclude septic arthritis, which may coexist.
Serum urate measurement timing
Serum urate is commonly normal (<6 mg/dL) during acute flares because acute inflammation drives urate into tissues. A normal urate in a flare never excludes gout. Retest 2-4 weeks after flare resolution for a reliable baseline. Chronically elevated urate without gout (asymptomatic hyperuricemia) does not warrant ULT unless urate >9 mg/dL with associated risk.
Imaging
- Plain radiographs show punched-out juxta-articular erosions with overhanging edges in chronic gout. Early gout has normal films.
- Musculoskeletal ultrasound detects the double-contour sign (MSU on cartilage surface—highly specific) and tophi within 1-2 years of disease onset.
- Dual-energy CT (DECT) color-codes MSU deposits with 85-90 percent sensitivity for tophi and is useful when diagnosis is uncertain and crystal analysis is unavailable.
ACR/EULAR 2015 classification criteria
Developed for clinical research; a score ≥8 supports gout. Demonstration of MSU crystals in a symptomatic joint/bursa is sufficient alone. Scored items include joint pattern (MTP1 = 2 points), symptom episode characteristics, clinical tophus, serum urate level (>10 = 4 points), imaging (double-contour sign, DECT deposits), and erosions. A gout diagnosis is clinical in most patients with classic podagra and responding to colchicine/NSAIDs; crystal confirmation is ideal for every patient but often deferred in uncomplicated cases.
S3. Acute Flare Management
Three effective first-line options exist; choose based on comorbidities, not on perceived flare severity.
NSAIDs
Fast, inexpensive, and effective. Indomethacin 50 mg PO TID × 3-5 days or naproxen 500 mg PO BID × 5-7 days. Avoid in CKD (eGFR <30), active peptic ulcer disease, heart failure, anticoagulation, and cirrhosis. Add a proton pump inhibitor in any patient over 60 or with prior PUD.
Colchicine (low-dose pulsed)
Preferred when started within 24-36 hours of flare onset. Colchicine 1.2 mg PO × 1, then 0.6 mg PO 1 hour later, then 0.6 mg PO BID starting 12 hours later until flare resolves (typically 2-3 days). Low-dose pulsed regimen (total first-day dose 1.8 mg) is equally effective to high-dose and markedly less toxic. Reduce 50 percent for CrCl 30-50 mL/min, avoid for CrCl <30 if on dialysis, and avoid with strong CYP3A4 inhibitors (clarithromycin, ritonavir) or P-glycoprotein inhibitors (cyclosporine, verapamil)—fatal toxicity has occurred.
Glucocorticoids
First-line when NSAIDs and colchicine are contraindicated. Prednisone 30–40 mg PO daily × 5 days without taper for monoarticular/oligoarticular flare. Intra-articular triamcinolone triamcinolone 40 mg IA is preferred for single large-joint flare. IV methylprednisolone 20 mg for inpatients unable to take PO.
IL-1 blockers (refractory or contraindicated)
Anakinra anakinra 100 mg SC daily × 3 days or canakinumab 150 mg SC single dose for patients with contraindications to all three first-line options, severe comorbid CKD/HF/active bleeding, or polyarticular flares unresponsive to 48-72 hours of first-line therapy. Cost is high and insurance authorization is typically required.
| Comorbidity | Preferred first-line | Avoid |
|---|---|---|
| Normal renal function, no PUD | NSAID or colchicine | — |
| CKD stage 3-4 | Glucocorticoid (PO or IA) | NSAIDs; reduce colchicine 50% |
| CKD stage 5 / dialysis | Glucocorticoid (PO or IA) | NSAIDs and colchicine |
| Peptic ulcer / GI bleeding | Colchicine or glucocorticoid | NSAIDs |
| Heart failure | Colchicine or intra-articular steroid | NSAIDs (volume retention); systemic steroids if fragile |
| Diabetes | NSAID or colchicine | High-dose systemic steroid (glycemic excursion) |
| Anticoagulated | Glucocorticoid or colchicine | NSAIDs |
| Polyarticular, refractory | Systemic glucocorticoid; IL-1 blocker if failure | IA injection (impractical for many joints) |
Do not stop urate-lowering therapy during an acute flare. Fluctuations in urate worsen and prolong flares. If ULT has not yet been started and the patient is a candidate, begin after flare resolution with anti-inflammatory prophylaxis co-administered.
Step-by-step management
Gout: urate-lowering therapy to target
Who needs ULT
- Start ULT: ≥2 flares per year, subcutaneous tophi or radiographic damage
- First flare: not routine unless CKD stage ≥3, urate >9 mg/dL or urolithiasis
HLA‑B*5801 before allopurinol
- Test Southeast Asian (Han Chinese, Korean, Thai) and Black patients
- Positive: no allopurinol; febuxostat instead (boxed warning in CVD)
Start allopurinol low
- Allopurinol 100 mg PO daily; eGFR 30–60: 50 mg daily
- eGFR 15–30: 50 mg every other day; 5–15: twice weekly; <5: once weekly
Caution: Azathioprine/6‑MP: avoid allopurinol, or if unavoidable cut AZA/6‑MP dose by 75%; febuxostat contraindicated.
Prophylaxis alongside ULT
- Colchicine 0.6 mg PO daily or BID; CrCl <30: start 0.3 mg daily; dialysis: 0.3 mg twice weekly
- Avoid colchicine with strong CYP3A4 or P‑gp inhibitors
Titrate to urate <6 mg/dL
- Raise allopurinol by 100 mg every 2–5 weeks, up to 800 mg daily if needed
- eGFR <60: raise by 50 mg every 2–4 weeks instead
- At target: urate every 6 months; continue ULT for life, even through flares
S4. Urate-Lowering Therapy (ULT)
Who should receive ULT
ACR 2020 strongly recommends ULT for any patient with: ≥2 flares per year, one or more subcutaneous tophi, radiographic damage attributable to gout, OR any of: CKD stage ≥3, serum urate >9 mg/dL, and urolithiasis. ACR gives conditional recommendation against routine ULT after a first flare unless one of the above features is present. Shared decision-making with the patient is emphasized because ULT is lifelong.
Allopurinol — first-line
Start low, go slow, and titrate to target. Allopurinol 100 mg PO daily (50 mg daily if eGFR <60), with dose increase of 100 mg every 2-5 weeks until serum urate <6 mg/dL. Typical effective doses are 300-600 mg daily; ACR 2020 permits titration to 800 mg daily in resistant cases. Low starting dose dramatically reduces AHS (allopurinol hypersensitivity syndrome), which carries 20-25 percent mortality when severe cutaneous features appear.
HLA-B*5801 screening: test before initiation in patients of Southeast Asian descent (Han Chinese, Thai, Korean), Black ancestry, or with any prior allopurinol reaction. Allele frequency: Han Chinese 6-8%, Korean 12%, Thai 10%, Black 3-4%, European <1%. Positive test contraindicates allopurinol; switch to febuxostat or probenecid. Check CBC and LFTs at baseline, 3 months, then annually.
Drug interactions: allopurinol inhibits xanthine oxidase and increases toxicity of 6-mercaptopurine and azathioprine (reduce those by 75%). Avoid co-administration with ampicillin/amoxicillin (rash).
Febuxostat — alternative XO inhibitor
Dose febuxostat 40 mg PO daily, increase to 80 mg daily after 2-4 weeks if urate remains >6. No renal dose adjustment needed (eGFR ≥30). Do not need HLA-B*5801 screening. CV safety signal: CARES trial showed higher all-cause and cardiovascular mortality versus allopurinol in patients with established CVD, leading to FDA boxed warning. Reserve for patients who cannot tolerate allopurinol or have contraindications. Review CV risk and involve the patient in decision-making.
Probenecid — uricosuric
Probenecid 250 mg PO BID × 7 days, then 500 mg PO BID, titrating to 1-2 g BID. Effective for underexcretors with preserved renal function (eGFR >50). Contraindicated in urolithiasis, CKD <50, and tumor lysis risk. Advise fluid intake ≥2 L/day and urinary alkalinization if baseline stone former. Interacts with penicillins, methotrexate, and ketorolac (elevated levels).
Pegloticase — refractory tophaceous gout
Recombinant uricase converts urate to allantoin. Pegloticase 8 mg IV q2 weeks with methotrexate 15 mg weekly co-administered to reduce anti-drug antibody formation. Reserved for severe refractory gout with visible tophi after failure of maximum XO inhibitor plus uricosuric. Do not use with G6PD deficiency (hemolysis). Monitor urate before each infusion; loss of efficacy (urate rising before the next dose) signals antibody formation and warrants discontinuation.
Anti-inflammatory prophylaxis during ULT
Crystal mobilization during urate lowering triggers flares in 40-60 percent of patients during the first 3-6 months. Start prophylaxis concurrently with ULT and continue for at least 3-6 months after target urate achieved.
- Colchicine 0.6 mg PO daily or BID (first-line; reduce for CKD)
- Naproxen 250 mg PO BID (if no NSAID contraindication)
- Prednisone 5–10 mg PO daily (if colchicine and NSAID contraindicated)
Titration schedule summary
| Week | Action | Monitoring |
|---|---|---|
| Week 0 | HLA-B*5801 (if indicated), baseline urate, CBC, LFTs, eGFR; start allopurinol 100 mg (or 50 in CKD) + colchicine prophylaxis | Patient education on ULT continuation during flares |
| Week 2-4 | Repeat serum urate; if >6 mg/dL, increase allopurinol by 100 mg | Assess for rash, pruritus, flare frequency |
| Week 8-12 | Continue titration to target; reach 300-500 mg typical | CBC, LFTs at 3 months |
| Month 6 | Confirm urate <6 mg/dL sustained; continue prophylaxis for additional 3 months | Reassess tophus size, flare frequency |
| Month 9-12 | Consider tapering prophylaxis if no flares and target achieved; maintain ULT indefinitely | Annual CBC, LFTs, eGFR, urate |
S5. Comorbidities and Referral
Cardiovascular and metabolic
Gout clusters with obesity, hypertension, dyslipidemia, CKD, and cardiovascular disease. Select antihypertensives with urate-lowering effects (losartan lowers urate by ~1 mg/dL; amlodipine neutral), avoid thiazides where alternatives exist, prefer fenofibrate over gemfibrozil for dyslipidemia, and SGLT2 inhibitors in diabetics (reduce urate and cardio-renal events). Weight reduction of 10 percent lowers urate by approximately 1 mg/dL. Dietary Approaches to Stop Hypertension (DASH) pattern reduces both BP and urate.
Chronic kidney disease
Gout is both common in and a contributor to CKD progression. Allopurinol is safe across all CKD stages with appropriate dose reduction (start 50 mg daily for eGFR <60; 50 mg every other day for dialysis). Observational data suggest slower eGFR decline with urate control, though randomized trials (PERL, CKD-FIX) did not show renal protection in non-gout hyperuricemia. ULT remains recommended in CKD patients with true gout.
Organ transplant gout
Calcineurin inhibitors (cyclosporine, tacrolimus) impair urate excretion. Avoid colchicine in these patients (P-gp interaction causes toxicity). Low-dose prednisone or IA steroid for flares; allopurinol with careful dosing for long-term ULT. Febuxostat is useful because it lacks significant calcineurin interaction. Check azathioprine use—allopurinol is contraindicated; reduce azathioprine by 75 percent if unavoidable.
When to refer
S6. Practice Insights
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Allopurinol is prescribed at 300 mg and left there while the urate never reaches target, so the corrections gout care needs — all center on three ACR 2020 paradigm shifts: treat-to-target serum urate below 6 mg/dL with structured allopurinol titration to whatever dose is required (often 600-800 mg, not the historical 300 mg ceiling), urate-lowering therapy initiation during acute flares rather than after resolution, and HLA-B*5801 screening before allopurinol in high-risk ethnicities. The four observations below capture how experienced clinicians navigate each.
What the Guideline Misses
The ACR 2020 guideline explicitly endorses urate-lowering therapy (ULT) initiation during acute gout flares — overturning the long-held practice of waiting for flare resolution before starting ULT. The CHISTOFER and START trials demonstrated no difference in flare duration or severity with concurrent ULT initiation versus delayed initiation, and the practical benefit is that patients actually start their long-term medication. In experienced hands ULT is now initiated at the visit where acute flare is treated, with anti-inflammatory prophylaxis (colchicine 0.6 mg daily) co-prescribed for 3-6 months. The historical “wait and start later” approach loses approximately 40 percent of patients to follow-up before ULT initiation ever happens.
Patterns That Repeat in Practice
The most consequential undertreatment seasoned clinicians see is allopurinol stuck at the historical 300 mg ceiling, with serum urate persistently above target (6 mg/dL). The ACR 2020 guideline explicitly supports titration up to 800 mg daily as needed to reach SU below 6, with monitoring for hypersensitivity and renal toxicity. In experienced hands the average effective allopurinol dose is approximately 450-600 mg, with many patients requiring 700-800 mg, particularly those with high baseline SU or tophaceous disease. The “300 mg is the dose” anchoring is the most common reason for treatment failure experienced practitioners see in referral patients.
Bedside Heuristic
experienced clinicians screen HLA-B*5801 before allopurinol initiation in patients of Korean, Han Chinese, or Thai descent, where carrier frequency exceeds 7-10 percent and confers substantial risk of allopurinol hypersensitivity syndrome (Stevens-Johnson, toxic epidermal necrolysis) with mortality approaching 25 percent. ACR 2020 strongly recommends screening in these high-risk groups. Positive HLA-B*5801 carriers receive febuxostat as alternative ULT. The screening test costs minimally compared with the catastrophic complication it prevents.
What Experienced Practice Now Does Differently
seasoned clinicians now co-administer methotrexate (15 mg weekly) or mycophenolate mofetil with pegloticase infusions in patients with tophaceous gout receiving the agent. The MIRROR-RCT trial demonstrated approximately 71 percent treatment success with methotrexate co-administration versus approximately 39 percent with pegloticase alone — the difference is anti-drug antibody formation that the immunosuppression prevents. In experienced hands every pegloticase recipient gets methotrexate co-administration unless contraindicated, and the durable response rates have improved measurably.
The Case That Cemented Allopurinol Titration
A man in his late 60s with 15 years of gout, multiple tophi at MTP and elbow, and chronic kidney disease stage 3a had been on allopurinol 300 mg daily for 5 years. His serum urate had been stable at 7.4 mg/dL throughout this period. The covering team had not titrated higher citing “renal adjustment limits.” He had 4-5 acute flares per year despite the established ULT.
clinicians titrated his allopurinol from 300 mg by 100 mg every 4 weeks while monitoring renal function and AST/ALT. By 16 weeks he was on 700 mg daily with SU 5.4 mg/dL. Over the subsequent 12 months he had only 1 acute flare (compared with 4-5 in prior years) and several of his smaller tophi began to soften and reduce in size. His renal function remained stable. The ACR 2020 explicit endorsement of dose titration above 300 mg, even in CKD when carefully monitored, supported the approach.
What clinicians took from this case is that the historical “300 mg is the dose” anchoring is wrong. Allopurinol should be titrated to whatever dose achieves SU below 6, with structured renal and hepatic monitoring; the 800 mg daily ceiling is the formal limit and most patients respond well within that range.
Four Deviations Experienced Practitioners Make From the Standard Protocol
- ULT initiated DURING acute flare, not after resolution. ACR 2020 endorses concurrent initiation; CHISTOFER and START trials confirm no flare-extending harm. Historical “wait and start later” loses ~40% of patients to follow-up before ULT begins.
- Allopurinol titration to whatever dose achieves SU <6 mg/dL, no fixed 300 mg ceiling. Average effective dose 450-600 mg; many patients need 700-800 mg. Titrate 100 mg q4 weeks with renal/hepatic monitoring.
- HLA-B*5801 screening before allopurinol in Korean/Han Chinese/Thai patients. Carrier frequency 7-10%, allopurinol hypersensitivity mortality ~25%. Positive carriers → febuxostat alternative. Cost minimal compared with catastrophic complication.
- Methotrexate (15 mg weekly) or MMF co-administration with pegloticase in tophaceous gout. MIRROR-RCT: ~71% success with MTX vs ~39% pegloticase alone. Immunosuppression prevents anti-drug antibody formation, dramatically improving durable response.
S7. Pearls, Pitfalls, and FAQ
🔑 Pearls
1. Start ULT during or immediately after a flare is fine. Old teaching was to wait 2-4 weeks; modern evidence shows concurrent initiation with anti-inflammatory coverage is acceptable and improves adherence. Do not delay.
2. Never stop ULT during a flare. Fluctuating urate worsens crystal mobilization. Treat the flare, continue the ULT, and reassure the patient that breakthrough flares are common in the first 3-6 months and will diminish.
3. Tophi are reversible. With sustained urate <6, subcutaneous tophi shrink over months to years; urate <5 accelerates resolution. Measure and photograph tophi at baseline to track response.
4. Probenecid is undervalued. For younger patients with preserved renal function and underexcretion, probenecid is highly effective and spares the HLA-B*5801 and CV-signal concerns. Maintain hydration and consider urinary alkalinization.
⚠️ Pitfalls
1. Starting allopurinol at 300 mg. This outdated “one-size-fits-all” dose doubled AHS rates. Start 100 mg (or 50 in CKD) and titrate—slow-and-steady protects the patient.
2. Stopping ULT when the patient “feels better.” Recurrence within 1 year of ULT withdrawal approaches 80 percent. ULT is lifelong; counsel patients explicitly.
3. Missing septic arthritis. A patient with gout can get bacterial infection. If a joint is acutely inflamed and the patient appears unusually unwell (fever, bacteremia risk), aspirate and send Gram stain plus culture even if you believe it is gout.
4. Colchicine overdose in renal failure or with CYP3A4/P-gp inhibitors. Fatal toxicity (multiorgan failure, bone marrow failure) has occurred when colchicine is combined with clarithromycin, cyclosporine, or tacrolimus. Review the medication list at every visit.
What is the serum urate target for urate-lowering therapy?
Who needs HLA-B*5801 testing before allopurinol?
Do I need to give anti-inflammatory prophylaxis when starting urate-lowering therapy?
- Ehlers-Danlos Syndromes: Hypermobile, Vascular, and Classical Subtypes
- Sarcoid Arthropathy: Löfgren Syndrome, Chronic Sarcoid Arthritis, Imaging, and Treatment
- Ankylosing Spondylitis: ASAS Classification, Imaging, and Biologic Therapy Pathways
- Systemic Lupus Erythematosus: EULAR 2023 Diagnosis and Immunosuppressive Management
- Adult-Onset Still Disease: Diagnosis and Management
- Behcet Disease: Diagnosis and Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ACR 2020 Guideline for the Management of Gout (Arthritis & Rheumatology · 2020)